Merck Likely to Post Inline Q2 Revenue, RBC Says
() -- Merck's (MRK) Q2 revenue is likely to be in line with consensus estimates as its Keytruda immunotherapy and Gardasil HPV vaccine sales are tracking at expected levels, RBC Capital Markets said in a Wednesday research report. The brokerage said its revenue estimate for fiscal 2026 is higher than the company's guid